Anti-thrombotics and major adverse cardiovascular events in anti-phospholipid syndrome: a cross-sectional study using the 2016-2018 National Inpatient Sample database

CONCLUSION: Patients with APS are most likely to benefit from anti-coagulant therapy in reducing MACE. Furthermore, anti-platelets alone or in combination with anti-coagulants are probably not beneficial in MACE reduction and may even increase risk.PMID:37584636 | DOI:10.1080/03009742.2023.2238402
Source: Scandinavian Journal of Rheumatology - Category: Rheumatology Authors: Source Type: research